The FDA on Thursday finalized two guidance documents related to next-generation sequencing (NGS) and drafted new guidance on investigational in vitro diagnostics (IVDs) in oncology trials – all of which offer recommendations to provide test developers with a more efficient path to market.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,